BPC-157 vs KPV (Alpha-MSH Fragment)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
BPC-157
250–500 mcg
KPV (Alpha-MSH Fragment)
300–500 mcg
Frequency
BPC-157
Once daily
KPV (Alpha-MSH Fragment)
Once daily
Administration
BPC-157
Subcutaneous injection
KPV (Alpha-MSH Fragment)
Oral
Cycle length
BPC-157
4-6 weeks
KPV (Alpha-MSH Fragment)
Ongoing/indefinite
Onset speed
BPC-157
Moderate (1-2 weeks)
KPV (Alpha-MSH Fragment)
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
KPV (Alpha-MSH Fragment)
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Anti-Inflammatory
Gut Health
Healing & Recovery
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
KPV (Alpha-MSH Fragment)
Molecular formula
C16H30N4O4
Molecular weight
342.43 Da
Half-life
Short peptide half-life; improved by nanoparticle and hydrogel formulations
Bioavailability
Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
CAS number
67727-97-3
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
KPV (Alpha-MSH Fragment)
Subcutaneous
200 mcg
Once daily · 4-6 weeks
Lower end of the subcutaneous practice range for systemic anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH and acts on NF-kB signaling [3][6].
300-500 mcg
Once daily · 4-6 weeks
Most commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
Oral
1000-1500 mcg
Once daily · 4-6 weeks
Oral route is used for gut-directed effects (e.g., IBD/ulcerative colitis models), taking advantage of PepT1 uptake; preclinical colitis studies support this application, doses are research practice [2][6].
Topical
0.01-0.1% cream or serum
Twice daily · 7-14 days (acute) up to 4-8 weeks (chronic)
Applied as a 0.01-0.1% topical formulation to affected skin for localized inflammation (eczema, rosacea, post-procedure redness); penetration enhancers are often added. Research/practice use [6].
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
KPV (Alpha-MSH Fragment)
Inflammatory bowel disease research
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][4].
Gut anti-inflammatory therapy development
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2][4].
Skin inflammation and wound healing
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
Cytokine-mediated inflammation studies
KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
KPV (Alpha-MSH Fragment)
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- Not approved for human clinical use
- Unknown interactions with immunosuppressive medications
- Insufficient safety data for pregnancy and lactation
- Potential melanocortin receptor effects in susceptible individuals
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose KPV (Alpha-MSH Fragment) if...
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies